(J Am Heart Assoc. 2016;5:e003200 doi: [10.1161/JAHA.116.003200](10.1161/JAHA.116.003200))

Introduction {#jah31418-sec-0004}
============

Aortic valve stenosis (AVS) is considered the most prevalent form of valve disease.[1](#jah31418-bib-0001){ref-type="ref"}, [2](#jah31418-bib-0002){ref-type="ref"} The number of people affected by this progressive and debilitating pathology will increase because of the aging population, causing an ever‐increasing public health burden.[3](#jah31418-bib-0003){ref-type="ref"} Traditionally, it was thought that AVS was related to valve degeneration attributed to aging, caused by several years of mechanical stress and biological response to such injury. However, more recently, several risks factors have been linked to the development of AVS, including male sex, hypertension, hyperlipidemia, smoking, advanced age, and congenital bicuspid valve morphology.[4](#jah31418-bib-0004){ref-type="ref"}, [5](#jah31418-bib-0005){ref-type="ref"} Overall, AVS pathogenesis is a multifactorial process and seems to be related to coronary atherosclerosis. In detail, an important link between AVS and early stages of coronary atherosclerotic plaque has been hypothesized,[6](#jah31418-bib-0006){ref-type="ref"}, [7](#jah31418-bib-0007){ref-type="ref"}, [8](#jah31418-bib-0008){ref-type="ref"} and a multitude of studies have been published regarding the associations between AVS, coronary artery disease (CAD), and coronary artery bypass grafting (CABG).[9](#jah31418-bib-0009){ref-type="ref"}, [10](#jah31418-bib-0010){ref-type="ref"}, [11](#jah31418-bib-0011){ref-type="ref"}, [12](#jah31418-bib-0012){ref-type="ref"} In addition, a very recent study by Boudoulas et al.[13](#jah31418-bib-0013){ref-type="ref"} describes the association between aortic stenosis and CABG focusing on valve morphology and concluding that "the incidence of coronary artery disease is extremely high in patients with aortic stenosis and tricuspid aortic valve." However, literature data are not consistent about this issue, and data about such an association have been challenged. In addition, the critical review of available studies highlights that, in most cases, only univariate unadjusted analyses were used, seldom taking into account for potential confounders. Thus, the aim of this study was to perform a meta‐analysis of literature studies enrolling patients undergoing aortic valve surgery to assess whether aortic valve morphology (tri‐ or bicuspid) impacts on prevalence of CAD, concomitant CABG, and postoperative mortality. In addition, to assess the presence of potential confounders, we evaluated the impact of distribution of major clinical and demographic variables between patients with bi‐ or tricuspid aortic valve.

Methods {#jah31418-sec-0005}
=======

A protocol for this review was prospectively developed, detailing the specific objectives, criteria for study selection, outcomes, and statistical methods.

Search Strategy {#jah31418-sec-0006}
---------------

To identify all available studies pertaining to prevalence of CAD, defined by atherosclerosis of 1 or more arteries that supply blood to the heart causing oxygen deficiency in the myocardium, we included articles with anamnestic CAD also when it was not specified whether it was anatomical CAD (70% stenosis or greater in at least 1 major coronary artery) or clinical CAD (previous acute myocardial infarction or percutaneous coronary intervention). A detailed search was conducted according to PRISMA (Preferred Reporting Items for Systematic reviews and Meta‐Analyses) guidelines[14](#jah31418-bib-0014){ref-type="ref"} to identify all concomitant myocardial surgical revascularization (CABG) and postoperative mortality in patients with bicuspid aortic valve (BAV) and tricuspid aortic valve (TAV) undergoing aortic valve surgery. A systematic search was performed in the electronic databases (PubMed, Web of Science, Scopus, and EMBASE), using the following search terms in all possible combinations: tricuspid aortic valve; bicuspid aortic valve; coronary artery disease; coronary artery bypass; myocardial infarction; mortality; and death. The last search was performed in November 2015. The search strategy was developed without any language or publication year restriction. In addition, the reference lists of all retrieved articles were manually reviewed. In case of missing data, the authors were contacted by e‐mail to try to retrieve original data. Two independent authors (P.P. and M.N.D.D.M.) analyzed each article and performed the data extraction independently. In case of disagreement, a third investigator was consulted (L.C.). Discrepancies were resolved by consensus. Selection results have been reported according to the PRISMA flow chart (Figure [1](#jah31418-fig-0001){ref-type="fig"}).

![PRISMA flow diagram. BAV indicates bicuspid aortic valve; CT, computed tomography.](JAH3-5-e003200-g001){#jah31418-fig-0001}

Data Extraction and Quality Assessment {#jah31418-sec-0007}
--------------------------------------

According to the prespecified protocol, all studies evaluating prevalence of CAD or use of CABG or postoperative mortality in patients with BAV and in those with TAV undergoing aortic valve replacement were included in the analysis. Case reports, reviews, animal studies, and studies on natural history of patients with aortic valve disease (not undergoing surgery) were excluded. In each study, data regarding sample size, major clinical and demographic variables, number of patients with CAD, and number of those undergoing CABG and those dying postoperatively were extracted. Formal quality score adjudication was not used, because previous investigations failed to demonstrate its usefulness.[15](#jah31418-bib-0015){ref-type="ref"}

Statistical Analysis and Risk of Bias Assessment {#jah31418-sec-0008}
------------------------------------------------

Statistical analysis was carried out using Comprehensive Meta‐analysis (version 2 \[2005\]; Biostat, Englewood, NJ). Differences among BAV and TAV subjects were expressed as mean difference (MD) with pertinent 95% CIs for continuous variables, and as odds ratio (OR) with pertinent 95% CI for dichotomous variables. Overall effect was tested using *Z* scores, and significance was set at *P*\<0.05. Statistical heterogeneity among studies was assessed with the chi‐square Cochran\'s Q test and with the I^2^ statistic, which measures the inconsistency across study results and describes the proportion of total variation in study estimates, that is, attributed to heterogeneity rather than sampling error. In detail, I^2^ values of 0% indicate no heterogeneity, 25% low, 25% to 50% moderate, and 50% high heterogeneity.[16](#jah31418-bib-0016){ref-type="ref"}

Publication bias was assessed by the Egger test and represented graphically by funnel plots of the standard difference in means versus SE. Visual inspection of funnel plot asymmetry was performed to address for possible small‐study effect, as well as the Egger test to address publication bias, over and above any subjective evaluation. *P*\<0.10 was considered statistically significant.[17](#jah31418-bib-0017){ref-type="ref"} In order to be as conservative as possible, the random‐effect method was used to take into account the variability among included studies.

Metaregression Analyses {#jah31418-sec-0009}
-----------------------

We hypothesized that differences in prevalence of CAD, use of CABG, or postoperative mortality between BAV and TAV patients may be affected by differences in clinical and demographic characteristics of patients included in different studies (mean age, sex, body mass index \[BMI\], hypertension, diabetes mellitus, hyperlipidemia, and smoking habit). To assess the possible effect of such variables in explaining the different results observed across studies, we planned to perform metaregression analyses after implementing a regression model with prevalence of CAD, use of CABG, or postoperative mortality between BAV and TAV patients as dependent variables (*y*) and the variables mentioned above as independent variables (*x*).

Results {#jah31418-sec-0010}
=======

After excluding duplicate results, the search retrieved 282 articles. Of these studies, 232 were excluded because they were off the topic after scanning the title and/or the abstract and 19 because they were reviews/comments/case reports or they lacked data of interest.

Thus, 31 articles (3017 BAV patients and 4586 TAV patients) were included in the final analysis (Figure [1](#jah31418-fig-0001){ref-type="fig"}). In detail, 15 studies with data on prevalence of CAD (1163 BAV and 2234 TAV patients), 16 reporting on use of CABG (1782 BAV and 1886 TAV patients), and 16 on postoperative mortality rate (1067 BAV and 2399 TAV patients) were included.

Study Characteristics {#jah31418-sec-0011}
---------------------

Major characteristics of the 31 studies included in the meta‐analysis are shown in Table [1](#jah31418-tbl-0001){ref-type="table-wrap"}.

###### 

Demographic and Clinical Data of BAV and TAV

  Author (Year)                                               Reported Outcomes      Observation Time         Subjects   Age, y                                      Males   Hypertension   Hyperlipidemia   Diabetes   BMI    Smoking
  ----------------------------------------------------------- ---------------------- ------------------ ----- ---------- ------------------------------------------- ------- -------------- ---------------- ---------- ------ ---------
  Abdulkareem 2013[18](#jah31418-bib-0018){ref-type="ref"}    CABG                                      BAV   192        58                                          71.3                                                      
                                                                                                        TAV   203        65                                          62.5                                                      
  Ali 2010[19](#jah31418-bib-0019){ref-type="ref"}            CABG, mortality        7 years            BAV   90         63                                          78.9    31.1           12.2             5.6               
                                                                                                        TAV   125        70                                          58.4    32.0           16.8             11.2              
  Asano 2012[20](#jah31418-bib-0020){ref-type="ref"}          CABG, mortality        5 years            BAV   86         46.3                                                                                                  
                                                                                                        TAV   58         70                                                                                                    
  Badiu 2010[21](#jah31418-bib-0021){ref-type="ref"}          CAD, CABG, mortality   5 years            BAV   11         37                                          100.0   45.5           9.1                                
                                                                                                        TAV   91         48                                          63.7    69.2           36.3             4.4               
  Boudoulas 2015[13](#jah31418-bib-0013){ref-type="ref"}      CABG                                      BAV   95         62                                          71.6    70             61               31                53
                                                                                                        TAV   175        71                                          55.4    87             60               47                48
  Branchetti 2014[22](#jah31418-bib-0022){ref-type="ref"}     CAD                                       BAV   74         55.5                                        64.9    31.1           27.0             5.4               43.2
                                                                                                        TAV   61         64.4                                        70.5    42.6           42.6             13.1              19.7
  Costopoulos 2014[23](#jah31418-bib-0023){ref-type="ref"}    Mortality              1 year             BAV   21         76.7                                        57.1    66.7                            28.6       26.6   
                                                                                                        TAV   447        79.8                                        47.4    77.2                            30.2       26.1   
  Davies 1996[24](#jah31418-bib-0024){ref-type="ref"}         CABG                                      BAV   296                                                                                                              
                                                                                                        TAV   125                                                                                                              
  Delius 1998[25](#jah31418-bib-0025){ref-type="ref"}         Mortality              10 years           BAV   16                                                                                                               
                                                                                                        TAV   31                                                                                                               
  Eleid 2013[26](#jah31418-bib-0026){ref-type="ref"}          CAD, CABG                                 BAV   47         58                                          76.6    68.1           48.9             8.5               23.4
                                                                                                        TAV   53         66                                          75.5    86.8           49.1             11.3              13.2
  Etz 2015[27](#jah31418-bib-0027){ref-type="ref"}            CAD, mortality         Inhospital         BAV   32         46.7                                        71.9    46.9                                              15.6
                                                                                                        TAV   347        61.6                                        63.7    72.0                            9.2               10.7
  Girdauskas 2014[28](#jah31418-bib-0028){ref-type="ref"}     Mortality              10 years           BAV   153        54                                          73.2    48.4                            11.1              35.9
                                                                                                        TAV   172        64                                          47.7    57.0                            15.7              40.1
  Holubec 2014[29](#jah31418-bib-0029){ref-type="ref"}        CAD, CABG, mortality   2 years            BAV   60         45[a](#jah31418-note-0003){ref-type="fn"}   81.7    45.0                                              
                                                                                                        TAV   40         59[a](#jah31418-note-0003){ref-type="fn"}   67.5    75.0                                              
  Hwang 2011[30](#jah31418-bib-0030){ref-type="ref"}          CAD, mortality         10 years           BAV   45         59.6                                        60.0    44.4           2.2              6.7               26.7
                                                                                                        TAV   43         58.3                                        48.8    23.3           2.3              9.3               9.3
  Jackson 2014[9](#jah31418-bib-0009){ref-type="ref"}         CAD                                       BAV   292        61.1                                        73.6    51.0                            11.3              
                                                                                                        TAV   355        717                                         69.9    74.6                            14.9              
  Kochman 2014[31](#jah31418-bib-0031){ref-type="ref"}        CAD, mortality         1 year             BAV   28         77.6                                        46.4    60.7                            39.3              
                                                                                                        TAV   84         79.1                                        47.6    65.5                            34.5              
  Kvitting 2013[32](#jah31418-bib-0032){ref-type="ref"}       CABG                                      BAV   63         43                                          79.4    36.5                            4.8        26     
                                                                                                        TAV   170        36                                          67.6    25.9                            2.4        24     
  Liu 2015[33](#jah31418-bib-0033){ref-type="ref"}            CAD, mortality         30 days            BAV   15         75.4                                        60.0    33.3                                       23.6   
                                                                                                        TAV   25         75.8                                        68.0    56.0                            12.0       21.7   
  Mosalanezhad 2014[34](#jah31418-bib-0034){ref-type="ref"}   CABG, mortality        8 years            BAV   30         42                                          93.3                                                      
                                                                                                        TAV   20         59                                          75.0                                                      
  Nakamura 2014[35](#jah31418-bib-0035){ref-type="ref"}       CAD                                       BAV   17         70                                          76.5    58.8           35.3             17.6              35.3
                                                                                                        TAV   59         77                                          52.5    79.7           33.9             20.3              40.7
  Philip 2015[10](#jah31418-bib-0010){ref-type="ref"}         CAD                                       BAV   200        57                                                  23.5           21.5             10.5              
                                                                                                        TAV   200        78                                                  76.5           78.5             31.5              
  Roberts 2003[11](#jah31418-bib-0011){ref-type="ref"}        CABG                                      BAV   232        64.7                                        72.0                                                      
                                                                                                        TAV   267        74                                          51.3                                                      
  Roberts 2007a[36](#jah31418-bib-0036){ref-type="ref"}       CABG, mortality        5 years            BAV   102                                                                                                              
                                                                                                        TAV   18                                                                                                               
  Roberts 2007b[37](#jah31418-bib-0037){ref-type="ref"}       CABG, mortality        4 years            BAV   187                                                                                                              
                                                                                                        TAV   235                                                                                                              
  Roberts 2007c[38](#jah31418-bib-0038){ref-type="ref"}       CABG                                      BAV   54                                                                                                               
                                                                                                        TAV   142                                                                                                              
  Roberts 2007d[39](#jah31418-bib-0039){ref-type="ref"}       CABG, mortality        13 years           BAV   180                                                                                                              
                                                                                                        TAV   107                                                                                                              
  Rylski 2014[12](#jah31418-bib-0012){ref-type="ref"}         CAD, mortality         Inhospital         BAV   41         55[a](#jah31418-note-0003){ref-type="fn"}   63.4    56.1                            9.8               
                                                                                                        TAV   588        61[a](#jah31418-note-0003){ref-type="fn"}   64.1    81.1                            9.2               
  Shim 2011[40](#jah31418-bib-0040){ref-type="ref"}           CAD                                       BAV   50         52                                          78.0    40.0           20.0             12.0       24.7   32.0
                                                                                                        TAV   50         52                                          78.0    50.0           28.0             8.0        25.2   42.0
  Stephan 1997[41](#jah31418-bib-0041){ref-type="ref"}        CABG                                      BAV   57         67                                          57.9                                                      
                                                                                                        TAV   57         73                                          54.4                                                      
  Warner 2013[42](#jah31418-bib-0042){ref-type="ref"}         CAD                                       BAV   10         46.5                                        60.0    50.0           40.0             10.0       30.1   10.0
                                                                                                        TAV   13         46.3                                        76.9    38.5           46.2                               23.1
  Yuan 2010[43](#jah31418-bib-0043){ref-type="ref"}           CAD                                       BAV   241        56.1                                        77.2    30.7           24.1             10.8              
                                                                                                        TAV   225        62.8                                        64.0    41.8           24.9                               

Data reported as median value. BAV indicates bicuspid aortic valve; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; TAV, tricuspid aortic valve.

The number of patients varied from 23 to 647, mean age from 36 to 79.8 years, and prevalence of male sex from 47.4% to 100%. Presence of hypertension was reported by 23.3% to 87.0% of patients, smoking habit by 9.3% to 53.0%, diabetes mellitus by 2.4% to 47.0%, and hyperlipidemia by 2.2% to 78.5%. Mean BMI varied from 21.7 to 30.1 kg/m^2^. Length of follow‐up for mortality assessment ranged from in‐hospital stay period to 13 years with a median of 5 years.

Coronary Artery Disease {#jah31418-sec-0012}
-----------------------

Fifteen studies,[1](#jah31418-note-1003){ref-type="fn"} for a total of 1163 BAV and 2234 TAV patients, showed that CAD was reported by 13.5% of BAV and 30.3% of TAV patients (OR, 0.33; 95% CI: 0.17, 0.65; *P*=0.001; Figure [2](#jah31418-fig-0002){ref-type="fig"}). Heterogeneity among studies was significant (I^2^=86%; *P*\<0.001), and it was not reduced by the exclusion of one study at a time. In addition, after excluding 2 studies by Kochman et al.[31](#jah31418-bib-0031){ref-type="ref"} and Liu et al.,[33](#jah31418-bib-0033){ref-type="ref"} including patients undergoing transcatheter aortic valve implantation (TAVI), the results were entirely confirmed (OR, 0.31; 95% CI: 0.14, 0.66; *P*=0.002; I^2^=88%; *P*\<0.001).

![Prevalence of coronary artery disease in patients with bicuspid (BAV) and tricuspid aortic valve (TAV).](JAH3-5-e003200-g002){#jah31418-fig-0002}

Concomitant CABG {#jah31418-sec-0013}
----------------

Sixteen studies,[2](#jah31418-note-1004){ref-type="fn"} reporting on 1782 BAV and 1886 TAV patients, showed that the number of patients undergoing concomitant CABG was significantly lower between BAV than TAV patients (31.0% vs 45.7%; OR, 0.45; 95% CI: 0.35, 0.59; *P*\<0.001; Figure [3](#jah31418-fig-0003){ref-type="fig"}). Heterogeneity among studies was significant (I^2^=56%; *P*=0.003). However, after excluding the study by Asano et al.,[20](#jah31418-bib-0020){ref-type="ref"} all results were confirmed without heterogeneity (OR, 0.49; 95% CI: 0.39, 0.61; *P*\<0.001; I^2^=37%; *P*=0.07).

![Prevalence of coronary artery bypass grafting (CABG) in patients with bicuspid (BAV) and tricuspid aortic valve (TAV).](JAH3-5-e003200-g003){#jah31418-fig-0003}

Postoperative Mortality {#jah31418-sec-0014}
-----------------------

The 16 studies[3](#jah31418-note-1005){ref-type="fn"} evaluating postoperative mortality showed a slightly significant difference in rate of mortality between BAV and TAV patients (16.2% vs 18.8%; OR, 0.62; 95% CI: 0.40, 0.97; *P*=0.04; I^2^=65%; *P*\<0.001; Figure [4](#jah31418-fig-0004){ref-type="fig"}). Interestingly, a metaregression analysis showed that the mortality rate was independent by the length of the observation (*Z* value: −1.17; *P*=0.240). In addition, we conducted a subanalysis removing the 3 studies[23](#jah31418-bib-0023){ref-type="ref"}, [31](#jah31418-bib-0031){ref-type="ref"}, [33](#jah31418-bib-0033){ref-type="ref"} that analyzed patients undergoing TAVI; the results did not differ from the previous ones (OR, 0.51; 95% CI: 0.32, 0.84; *P*=0.006; I^2^=63%; *P*=0.001).

![Post‐operative mortality in patients with bicuspid (BAV) and tricuspid aortic valve (TAV).](JAH3-5-e003200-g004){#jah31418-fig-0004}

Clinical and Demographic Variables {#jah31418-sec-0015}
----------------------------------

As showed in Figure S1, when major clinical and demographic characteristics have been compared between BAV and TAV patients, we found that BAV subjects were significantly younger than TAV (MD, −7.29; 95% CI: −11.17, −3.41; *P*\<0.001). In addition, BAV subjects were more frequently males (72.7% vs 60.1%; OR, 1.61; 95% CI: 1.33, 1.94; *P*\<0.001) and exhibited a lower prevalence of hypertension (43.0% vs 65.4%; OR, 0.58; 95% CI: 0.39, 0.87; *P*\<0.001) and diabetes (11.6% vs 16.3%; OR, 0.71; 95% CI: 0.54, 0.93; *P*=0.01) than TAV. In contrast, no significant differences were found in prevalence of hyperlipidemia and smoking habit as well as in mean BMI between BAV and TAV patients.

Interestingly, a metaregression analysis showed that younger age and lower prevalence of diabetes were associated with lower prevalence of CAD (*Z* value: −3.03; *P*=0.002 and *Z* value: −3.10; *P*=0.002, respectively; Figure [5](#jah31418-fig-0005){ref-type="fig"}) and CABG (*Z* value: −2.69; *P*=0.007 and *Z* value: −3.36; *P*=0.001, respectively; Figure [6](#jah31418-fig-0006){ref-type="fig"}) documented in BAV patients as compared to TAV patients.

![Meta‐regression analysis. Effect of the difference in mean age (A) and in prevalence of diabetes (B) on prevalence of coronary artery disease in patients with bicuspid (BAV) and tricuspid aortic valve (TAV).](JAH3-5-e003200-g005){#jah31418-fig-0005}

![Meta‐regression analysis. Effect of the difference in mean age (A) and in prevalence of diabetes (B) on prevalence of concomitant coronary artery bypass grafting in patients with bicuspid (BAV) and tricuspid aortic valve (TAV).](JAH3-5-e003200-g006){#jah31418-fig-0006}

Sensitivity Analysis {#jah31418-sec-0016}
--------------------

Given the statistically significant difference in distribution of age, sex, hypertension, and diabetes between BAV and TAV patients, all the analyses have been repeated after including only studies enrolling patients comparable for all these variables.[30](#jah31418-bib-0030){ref-type="ref"}, [33](#jah31418-bib-0033){ref-type="ref"}, [40](#jah31418-bib-0040){ref-type="ref"}, [41](#jah31418-bib-0041){ref-type="ref"}, [42](#jah31418-bib-0042){ref-type="ref"} Interestingly, the difference in prevalence of CAD (OR, 0.65; 95% CI, 0.33, 1.26; *P*=0.20) and mortality rate (OR, 1.77; 95% CI, 0.81, 3.87; *P*=0.15) were no longer significant. None of the 5 studies enrolling patients comparable for age, sex, hypertension, and diabetes provided information about concomitant CABG in BAV and TAV subjects. Thus, the sensitivity analysis was not performed for this outcome. When stratifying results according to the study design (retrospective or prospective), we found that the difference in CAD, concomitant CABG, and postoperative mortality between BAV and TAV patients were consistently confirmed only by retrospective studies. Interestingly, all the differences between the 2 groups were no longer significant in prospective studies (Table [2](#jah31418-tbl-0002){ref-type="table-wrap"}).

###### 

Stratification of the Studies: Retrospective and Prospective

                          No. of Studies   OR (95% CI)                     Heterogeneity
  ----------------------- ---------------- ------------------------------- -----------------------
  CAD                                                                      
  Retrospective studies   8                0.37 (0.18, 0.76; *P*=0.007)    I^2^: 84%; *P*\<0.001
  Prospective studies     7                0.30 (0.07, 1.32; *P*=0.11)     I^2^: 87%; *P*\<0.001
  CABG                                                                     
  Retrospective studies   15               0.45 (0.35, 0.59; *P*\<0.001)   I^2^: 59%; *P*=0.002
  Prospective studies     1                0.43 (0.02, 7.90; *P*=0.57)     Not evaluable
  Mortality                                                                
  Retrospective studies   13               0.57 (0.34, 0.94; *P*=0.03)     I^2^: 72%; *P*\<0.001
  Prospective studies     3                1.08 (0.41, 2.86; *P*=0.88)     I^2^: 0%; *P*=0.95

CABG indicates coronary artery bypass grafting; CAD, coronary artery disease; OR, odds ratio.

Publication Bias {#jah31418-sec-0017}
----------------

Because it is recognized that publication bias can affect results of meta‐analyses, we attempted to assess this potential bias using funnel plot visual analysis (Figure S2).

Visual inspection of funnel plots of effect size versus SE for studies evaluating CAD, CABG, and mortality in BAV and in TAV patients suggested a symmetric distribution of studies around the effect size, and the Egger test confirmed the lack of publication bias for all these outcomes (CAD, *P*=0.868; CABG, *P*=0.914; mortality, *P*=0.403).

Discussion {#jah31418-sec-0018}
==========

This meta‐analysis, which includes more than 7500 patients undergoing aortic valve surgery, shows, in agreement with previously published data, a lower prevalence of CAD (13.5% vs 30.3%) and concomitant CABG (31% vs 45.7%) in BAV than in TAV patients, accompanied by a marginally lower rate of postoperative mortality (16.2% vs 18.8%). We also show that BAV patients enrolled in the included studies were ≈7 years younger, more often males (72.7% vs 60.1%), and exhibited lower prevalence of hypertension (43.0% vs 65.4%) and diabetes (11.6% vs 16.3%) compared to TAV patients (Table S1).

Altogether, these data suggest that the lower cardiovascular risk reported in BAV patients may be partly explained by younger age and lower prevalence of some cardiovascular risk factors in this clinical setting. Interestingly, a meta‐regression analysis confirmed and extended this hypothesis, showing that age and diabetes have a profound impact on the difference in prevalence of CAD and CABG between BAV and TAV patients. Moreover, when the analyses have been repeated after including only those studies enrolling patients matched for age, sex, hypertension, and diabetes, the difference in prevalence of CAD and postoperative mortality were no longer significant between the 2 groups of patients. Thus, patients with BAV typically develop aortic stenosis at a younger age, usually before 65 years, compared to aortic stenosis in patients with TAV, which more often develops after age 70.[44](#jah31418-bib-0044){ref-type="ref"}

Several studies analyzed prevalence of CAD in BAV and TAV patients, concluding that this atherosclerotic disease is uncommon in BAV, but is associated with TAV disease.[9](#jah31418-bib-0009){ref-type="ref"}, [24](#jah31418-bib-0024){ref-type="ref"} However, recent developments suggest that "incidence of CAD is high in patients with aortic valve degeneration, both in those with tricuspid and bicuspid aortic valve."[13](#jah31418-bib-0013){ref-type="ref"}

Our analysis shows that although the incidence of all the considered variables is lower in BAV compared to TAV patients, a higher mean age and a higher prevalence of hypertension and diabetes is found in the TAV group. The potential impact of these confounding covariates should be taken into account. Indeed, our sensitivity analysis shows that once hypertension, sex, diabetes, and age are taken into account and only studies with patients comparable for these variables are included, the differences in prevalence of CAD between BAV and TAV patients is no longer significant.

The finding that, in the TAV group, higher mean age and increased prevalence of diabetes and hypertension are paralleled by a higher prevalence of CAD, concomitant CABG, and postoperative mortality somehow supports the hypothesis that the etiopathogenetic mechanism underling aortic valve degeneration is similar or complementary to coronary atherosclerosis. Indeed, recent evidence suggested that risk factors responsible for pathogenesis of atherosclerosis are also related to development of aortic calcification and stenosis.[13](#jah31418-bib-0013){ref-type="ref"}, [45](#jah31418-bib-0045){ref-type="ref"}, [46](#jah31418-bib-0046){ref-type="ref"} However, the reasons why many patients with CAD do not develop aortic stenosis are still under debate. The major explanation may reside in the anatomic variation in size and diameter in normal tricuspid aortic valve[47](#jah31418-bib-0047){ref-type="ref"} and the genetic predisposition to aortic calcification, such as lipoprotein(a) expression levels encoded by the lipoprotein(a) gene.[48](#jah31418-bib-0048){ref-type="ref"}

Another finding of our analysis is the marginally lower postoperative mortality in BAV than in TAV patients. Evaluating the risk of post operative mortality in BAV and TAV patients, it is interesting to highlight that the only study[19](#jah31418-bib-0019){ref-type="ref"} providing an adjusted multivariate analysis showed that valve morphology did not impact on mortality rate. Moreover, similar findings have been confirmed by Roberts et al.[37](#jah31418-bib-0037){ref-type="ref"}, [39](#jah31418-bib-0039){ref-type="ref"} by means of an unadjusted analysis. On the other hand, it is noteworthy to stress that 4 studies[20](#jah31418-bib-0020){ref-type="ref"}, [27](#jah31418-bib-0027){ref-type="ref"}, [28](#jah31418-bib-0028){ref-type="ref"}, [32](#jah31418-bib-0032){ref-type="ref"} consistently highlighted that an increasing age was the main predictor of postoperative mortality. Overall, these evidences confirm and extend our data suggesting that the difference in mean age between BAV and TAV might, at least in part, explain the difference in postoperative mortality documented in these 2 groups. Indeed, when we have analyzed only studies on patients comparable for age, sex, hypertension, and diabetes, the differences in postoperative mortality rate between BAV and TAV patients were no longer significant. In addition, after stratifying results according to study design, we found that differences between BAV and TAV patients were confirmed only by retrospective studies. Interestingly, all the differences between the 2 groups were no longer significant in prospective studies.

We recognize that our study has several potential limitations. The studies included in our meta‐analysis have different inclusion and exclusion criteria with no clear definition of CAD. In addition, most of the patients included in the analysis had concomitant cardiovascular risk factors. Given that meta‐analysis is performed on aggregate data and some missing information is present in each study, the multivariate approach allowed for the adjustment for some (but not all) potential confounders. Thus, although results of metaregression analyses were able to refine analyses by assessing the influence of most clinical and demographic variables on the observed results, caution is necessary in overall results interpretation. Moreover, heterogeneity among the studies was generally significant. Although it was not possible to conclusively ascertain sources of heterogeneity, publication bias did not affect results of our meta‐analysis.

In conclusion, patients undergoing aortic valve replacement might represent a potential bias. Patients undergoing surgery are a subset of patients with BAV or TAV, and this could influence the results. This might limit the reproducibility of reported results. However, a large study[49](#jah31418-bib-0049){ref-type="ref"} reporting on natural history of BAV and TAV patients not undergoing surgery confirmed the lack of difference in cardiovascular mortality between the 2 groups. In addition, the studies included analyzed not only aortic valve stenosis pathology, but also aortic valve regurgitation. However, in the studies analyzing both aortic valve pathologies,[18](#jah31418-bib-0018){ref-type="ref"}, [22](#jah31418-bib-0022){ref-type="ref"}, [26](#jah31418-bib-0026){ref-type="ref"}, [27](#jah31418-bib-0027){ref-type="ref"}, [35](#jah31418-bib-0035){ref-type="ref"} there are no significative differences between BAV and TAV groups.

A further potential confounder is represented by inclusion of studies analyzing patients' candidate for TAVI, who, besides the older age, have a greater prevalence of comorbidities. However, a subanalysis excluding these 3 studies[23](#jah31418-bib-0023){ref-type="ref"}, [31](#jah31418-bib-0031){ref-type="ref"}, [33](#jah31418-bib-0033){ref-type="ref"} confirmed all our findings.

In conclusion, the results of the meta‐analysis here presented shows that analysis of raw data clearly suggests an association of aortic valve morphology with prevalence of CAD, concomitant CABG, and postoperative mortality. Interestingly, differences in age and diabetes have a profound impact on prevalence of CAD and concomitant CABG between BAV and TAV patients. Thus, based on our analysis, BAV patients do not exhibit a lower risk of CAD compared to TAV patients. However, further studies or patient‐level meta‐analysis are needed to adjust results for potential confounders and definitely address this issue.
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**Figure S1.** Distribution of major clinical and demographic characteristics in patients with bicuspid (BAV) and tricuspid aortic valve (TAV). A, Sex, (B) age, (C) hypertension, (D) diabetes, (E) hyperlipedimia, (F) BMI, and (G) smoking. BMI indicates body mass index.

**Figure S2.** Funnel plots of effect size vs standard error for studies evaluating the prevalence of coronary artery disease (A), coronary artery bypass grafting (B), and postoperative mortality (C) in patients with bicuspid (BAV) and tricuspid aortic valve (TAV).

**Table S1.** Summary Table of Meta‐Analysis Results
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